| 2025-05-14 |
股东大会：
将于2025-06-27召开股东大会
会议内容 ▼▲
- 1.To elect the following four director nominees, each to serve until the 2026 annual meeting of shareholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal: Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Silverman;
2.To ratify the appointment of CBIZ CPAs P.C. as Oncocyte’s independent registered public accounting firm for the year ending December 31, 2025;
3.To approve, on a non-binding advisory basis, Oncocyte’s named executive officer compensation for the year ended December 31, 2024;
4.To approve an amendment to the Oncocyte Corporation Amended and Restated 2018 Equity Incentive Plan to increase the total number of shares of the Company’s common stock authorized for issuance under such plan by 1,500,000, to a total of 3,800,000 shares.
|
| 2025-05-12 |
详情>>
股本变动：
变动后总股本2859.93万股
变动原因 ▼▲
- 原因：
- From December 31, 2024 to March 31, 2025
Sale of common shares, net of financing costs
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-0.26美元,归母净利润-667.1万美元,同比去年增长28.54%
|
| 2025-05-12 |
财报披露：
美东时间 2025-05-12 盘后发布财报
|
| 2025-03-24 |
详情>>
业绩披露：
2024年年报每股收益-4.66美元,归母净利润-6092.6万美元,同比去年增长-112.12%
|
| 2025-02-07 |
详情>>
内部人交易：
James Andrea S.股份增加97561.00股
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.36美元,归母净利润-2741.5万美元,同比去年增长-118.83%
|
| 2024-09-25 |
股东大会：
将于2024-10-11召开股东大会
会议内容 ▼▲
- 1.To approve the amendment and restatement of our 2018 Equity Incentive Plan (as previously amended, the “Incentive Plan”) to: (a) provide for an additional 1,250,000 shares of our common stock to be available for the issuance of equity awards thereunder, such that the total number of shares of common stock that have been made available for issuance since the inception of the Incentive Plan is 2,300,000, (b) provide that the Board, or applicable Committee of the Board, may delegate, in its discretion, to one or more of our executive officers, the limited authority to grant awards under the Incentive Plan, subject to the limitations under the Incentive Plan with respect to the participants eligible to receive such awards and any other limitations and guidelines established by the Board, or applicable Committee of the Board, with respect to the exercise of such delegated authority, (c) eliminate “fungible share counting” in order to provide that any shares of our common stock granted in connection with any awards will be counted against the number of shares available for the grant of awards under the Incentive Plan as one share for every award, (d) eliminate the limitations on “share recycling” in order to provide that any shares of our common stock tendered in payment of an option, delivered or withheld by us to satisfy any tax withholding obligation, covered by a stock-settled award that were not issued upon the settlement of the award, or repurchased by us using the proceeds from option exercises, will again be made available for issuance under the Incentive Plan, and (e) eliminate the restrictions in the Incentive Plan that prohibit the terms of any award to provide for vesting, in whole or in part, prior to the date that is one year from the date on which the award is granted, in each case, as contemplated by an Amended and Restated 2018 Equity Incentive Plan (the “Amended and Restated Incentive Plan”);
2.To approve an adjournment of the Meeting in the event a quorum is not achieved;
3.To transact such other business as may properly come before the Meeting or any postponement or adjournment thereof.
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-1.32美元,归母净利润-1365.9万美元,同比去年增长-133.85%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-1.13美元,归母净利润-933.5万美元,同比去年增长-407.78%
|
| 2024-04-29 |
股东大会：
将于2024-06-28召开股东大会
会议内容 ▼▲
- 1.To elect the following four director nominees to hold office until the next Annual Meeting of Shareholders or until their earlier death, resignation, or removal: Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Silverman;
2.To ratify the appointment of Marcum LLP as Oncocyte’s independent registered public accounting firm for the year ending December 31, 2024;
3.To approve, on a non-binding advisory basis, Oncocyte’s named executive officer compensation for the year ended December 31, 2023.
|
| 2024-04-16 |
详情>>
业绩披露：
2023年年报每股收益-3.75美元,归母净利润-2872.3万美元,同比去年增长60.88%
|
| 2023-12-09 |
复牌提示：
2023-12-08 15:23:06 停牌，复牌日期 2023-12-08 15:33:07
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.68美元,归母净利润-1252.8万美元,同比去年增长55.60%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-0.83美元,归母净利润-584.1万美元,同比去年增长68.70%
|
| 2023-07-25 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2023-07-10 |
股东大会：
将于2023-07-21召开股东大会
会议内容 ▼▲
- 1.To approve granting our Board of Directors the authority to exercise its discretion to amend our Articles of Incorporation to effect a reverse stock split of our outstanding shares of Common Stock, to regain compliance with the Nasdaq Stock Market’s minimum bid price requirement, at any of the following exchange ratios at any time within one year after shareholder approval is obtained, and once approved by the shareholders, the timing of the amendment and the specific reverse split ratio to be effected shall be determined in the sole discretion of our Board of Directors:(a)a one-for-ten reverse stock split;(b)a one-for-fifteen reverse stock split;(c)a one-for-twenty reverse stock split;(d)a one-for-twenty-five reverse stock split;
2.To approve granting our Board of Directors the authority to exercise its discretion at any time within one year after shareholder approval is obtained to amend our Articles of Incorporation to reduce the number of authorized shares of our common stock, no par value (“Common Stock”), by a corresponding ratio to the reverse stock split if, and only if, the reverse stock split proposal is approved and implemented;
3.To approve an amendment to our 2018 Equity Incentive Plan (as amended, the “Incentive Plan”) to eliminate the limitation on the number of shares of our Common Stock that can be granted to any individual participant under the Incentive Plan during any one (1)-year period;
4.To transact such other business as may properly come before the Meeting or any adjournments of the Meeting.
|
| 2023-05-19 |
股东大会：
将于2023-06-23召开股东大会
会议内容 ▼▲
- 1.To elect five (5) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Joshua Riggs, Andrew Arno, Alfred D. Kingsley, Andrew J. Last and Louis E. Silverman;
2.To ratify the appointment of WithumSmith+Brown, PC as Oncocyte’s independent registered public accountants for the fiscal year ending December 31, 2023;
3.To approve, on an advisory basis, Oncocyte’s named executive officer compensation in fiscal 2022;
4.To approve an amendment to our 2018 Equity Incentive Plan (as amended, the “Incentive Plan”) to make an additional 5,000,000 shares of common stock available for equity awards;
5.To transact such other business as may properly come before the Meeting or any adjournments of the Meeting.
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益0.02美元,归母净利润303.30万美元,同比去年增长129.47%
|
| 2023-04-12 |
详情>>
业绩披露：
2022年年报每股收益-0.66美元,归母净利润-7342.2万美元,同比去年增长-14.55%
|
| 2022-06-08 |
股东大会：
将于2022-07-15召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Ronald Andrews, Jr., Andrew Arno, Jennifer Levin Carter, Melinda Griffith, Alfred D. Kingsley and Andrew J. Last;
2.To ratify the appointment of WithumSmith+Brown, PC as Oncocyte’s independent registered public accountants for the fiscal year ending December 31, 2022;
3.To approve, on an advisory basis, Oncocyte’s named executive officer compensation in fiscal 2021;
4.To approve, on an advisory basis, the frequency of future advisory votes on executive compensation;
5.To approve an amendment to our 2018 Equity Incentive Plan (as previously amended on June 24, 2021, the “Incentive Plan”) to eliminate “fungible share counting” in order to provide that any shares of common stock granted in connection with any awards will be counted against the number of shares available for the grant of awards under the Incentive Plan as one share for every award;
6.To approve, for purposes of complying with the Nasdaq Listing Rules, the issuance of shares of our common stock underlying securities issued by us to Broadwood in connection with our recent Preferred Stock Offer and Underwritten Offer, in an amount equal to 20% or more of our common stock outstanding;
7.To transact such other business as may properly come before the Meeting or any adjournments of the Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-21 |
股东大会：
将于2021-06-24召开股东大会
会议内容 ▼▲
- 1.To elect seven (7) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Ronald Andrews, Andrew Arno, Jennifer Levin Carter, Melinda Griffith, Alfred D. Kingsley, Andrew J. Last, and Cavan Redmond;
2.To ratify the appointment of OUM & Co. LLP as OncoCyte’s independent registered public accountants for the fiscal year ending December 31, 2021;
3.To approve an amendment to our Articles of Incorporation to increase the total number of authorized shares of common stock, no par value, that we may issue from 150,000,000 shares to 230,000,000 shares (the “Common Stock Amendment”);
4.To approve an amendment to our Articles of Incorporation to formally change our corporate name from OncoCyte Corporation to Oncocyte Corporation;
5.To approve an amendment to our 2018 Equity Incentive Plan (the “Incentive Plan”) to make an additional 10,000,000 shares of common stock available for equity awards;
6.To approve the adjournment of the Meeting if a quorum is not present or to provide additional time to solicit proxies for approval of the Common Stock Amendment;
7.To transact such other business as may properly come before the Meeting or any adjournments of the Meeting.
|
| 2020-05-26 |
股东大会：
将于2020-06-17召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Ronald Andrews, Andrew Arno, Melinda Griffith, Alfred D. Kingsley, Andrew J. Last, and Cavan Redmond;
2.To ratify the appointment of OUM & Co. LLP as OncoCyte’s independent registered public accountants for the fiscal year ending December 31, 2020;
3.To approve an amendment to our Articles of Incorporation to increase the total number of authorized shares of common stock, no par value, that we may issue from 85,000,000 shares to 150,000,000 shares (the “Common Stock Amendment”);
4.To approve the adjournment of the Meeting if a quorum is not present or to provide additional time to solicit proxies for approval of the Common Stock Amendment;
5.To transact such other business as may properly come before the Meeting or any adjournments of the Meeting.
|
| 2019-06-18 |
股东大会：
将于2019-07-17召开股东大会
会议内容 ▼▲
- 1.To elect seven (7) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Ronald Andrews, Andrew Arno, Melinda Griffith, Alfred D. Kingsley, Andrew J. Last, Aditya P. Mohanty, and Cavan Redmond;
2.To ratify the appointment of OUM & Co. LLP as OncoCyte’s independent registered public accountants for the fiscal year ending December 31, 2019;
3.To approve an amendment to our Bylaws to increase the authorized number of directors from the current minimum of four and maximum of seven to a minimum of six and a maximum of ten;
4.To approve an amendment to our 2018 Equity Incentive Plan (the “Incentive Plan”) that, if approved, will make an additional 6,000,000 shares of common stock available for equity awards;
5.To transact such other business as may properly come before the meeting or any adjournments of the meeting.
|
| 2018-07-30 |
股东大会：
将于2018-08-27召开股东大会
会议内容 ▼▲
- 1.To elect seven (7) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Ronald Andrews, William Annett, Andrew Arno, Alfred D. Kingsley, Andrew J. Last, Aditya P. Mohanty, and Cavan Redmond;
2.To ratify the appointment of OUM & Co. LLP as OncoCyte’s independent registered public accountants for the fiscal year ending December 31, 2018;
3.To approve a new Equity Incentive Plan (the “Incentive Plan”) that, if approved, will replace our current Employee Stock Option Plan and will make 5,000,000 shares of common stock available for the grant of stock options or other stock related equity;
4.To approve an amendment to our Articles of Incorporation to increase the total number of authorized shares of common stock, no par value, that we may issue from 50,000,000 shares to 85,000,000 shares;
5.To transact such other business as may properly come before the meeting or any adjournments of the meeting.
|
| 2017-04-28 |
股东大会：
将于2017-06-15召开股东大会
会议内容 ▼▲
- 1. To elect seven (7) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: William Annett, Andrew Arno, Don M. Bailey, Alfred D. Kingsley, Andrew J. Last, Aditya P. Mohanty, and Cavan Redmond;
2. To ratify the appointment of OUM & Co. LLP as OncoCyte’s independent registered public accountants for the fiscal year ending December 31, 2017;
3. To approve an amendment to our Employee Stock Option Plan (the “Option Plan”) that, if approved, will make an additional 1,200,000 shares of common stock available for sale or the grant of stock options or restricted stock awards;
4. To transact such other business as may properly come before the meeting or any adjournments of the meeting.
|
| 2016-04-29 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1. To elect seven (7) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: William Annett, Andrew Arno, Alfred D. Kingsley, Andrew Last, Aditya Mohanty, Cavan Redmond, and Michael D. West;
2. To ratify the appointment of OUM & Co. LLP as OncoCyte’s independent registered public accountants for the fiscal year ending December 31, 2016;
3. To transact such other business as may properly come before the meeting or any adjournments of the meeting.
|